Amazon coin set to soar 25X – starting December 16th?

This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024

Wendall Wierenga net worth and biography

Wendall Wierenga Biography and Net Worth

Director of Cytokinetics

Wendell Wierenga, Ph.D. has served as a member of our Board of Directors since February 2011. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc. From 2006 to 2011, he served as Executive Vice President, Research and Development at Ambit Biosciences Corporation. From 2003 to 2006, he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company). From 1990 to 2000, he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of XenoPort, Inc. since 2001, the Board of Directors of Ocera Therapeutics, Inc. since December 2013, the Board of Directors of Apricus Biosciences, Inc. and Concert Pharmaceuticals, Inc. since March 2014, and the Board of Directors of Anacor Pharmaceuticals, Inc. since September 2014. He also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.

What is Wendall Wierenga's net worth?: The estimated net worth of Wendall Wierenga is at least $1.20 million as of December 16th, 2024. Dr. Wierenga owns 24,559 shares of Cytokinetics stock worth more than $1,200,198 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Wierenga may own. Learn More about Wendall Wierenga's net worth.
How do I contact Wendall Wierenga?: The corporate mailing address for Dr. Wierenga and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Wendall Wierenga's contact information.
Has Wendall Wierenga been buying or selling shares of Cytokinetics?: During the last ninety days, Wendall Wierenga has sold $268,685.62 in shares of Cytokinetics stock. Most recently, Wendall Wierenga sold 742 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $48.61, for a transaction totalling $36,068.62. Following the completion of the sale, the director now directly owns 24,559 shares of the company's stock, valued at $1,193,812.99. Learn More on Wendall Wierenga's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 48 times. They sold a total of 454,133 shares worth more than $28,606,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 12/16/2024.

Wendall Wierenga Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Sell	742	$48.61	$36,068.62	24,559
10/28/2024	Sell	4,452	$52.25	$232,617.00	24,559
12/27/2023	Sell	10,000	$73.60	$736,000.00	18,653
8/21/2023	Sell	6,020	$32.02	$192,760.40	18,205
12/27/2021	Sell	4,166	$44.37	$184,845.42
4/28/2020	Sell	9,999	$16.00	$159,984.00	3,333

Wendall Wierenga Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $48.87

$46.85

$50.32

50 Day Range

MA: $52.09

$46.36

$58.62

2 Week Range

Now: $48.87

$36.24

$110.25

Volume

3,805,196 shs

Average Volume

1,988,956 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.